“…156 Similarly, the FDA requirements for informing PB recipients, for record keeping, and for post-treatment follow-up were not met. 157 These failures to comply with conditions of the FDA waiver would serve to seriously erode public trust and to question the validity of the decision for the Interim Rule.…”